BioAtla’s Q3 2025 update details FDA-aligned Oz-V Phase III trial, peak sales forecast, strategic deal progress, and cost reductions.

Globalstar, Inc. is rated a Strong Buy with a $69/share price target, citing future margin expansion and revenue growth. Read more on GSAT stock here.

Lab best practices 2026 focus on ISO 15189:2022 compliance, unified LIMS-ELN systems, and strengthened data integrity for ...

X9, Inc. today announced positive results from its first-in-human clinical feasibility study evaluating the X9 Ultrasound ...

Secures royalty economic interests in two early stage partnered assets through XOMA Royalty’s announced expected acquisition ...

Monash University’s vice chancellor says she’s kept “awake at night” by how to make “campuses safe and respectful” after ...

The international break may be a necessity (especially during a World Cup year), but it remains an annoying one. With no ...

Combine structured frameworks with a customizable assessment model to turn strategic fog into prioritized remediation plans ...

President Donald Trump has renewed his criticism of the NFL's new kickoff format, a rule change introduced with the intention of increasing returns while reducing injury risk. Al ...

Q3 2025 net product revenues grew to $14.3 million; Q3 2025 total net product revenues were $56.8 millionOperational pilot ...

“Global collaborations for European economic resilience” is the theme of SEMICON Europa 2025. The event is coming to Munich, ...

CISOs still struggle to prove the value of their security programs using metrics that their business leaders so desperately ...